Valuation dashboard for Belite Bio, Inc (BLTE) with P/E N/A, P/B 7.97, EV/EBITDA -53.7 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $154.01 (closing price, November 4, 2026), BLTE has negative trailing earnings (P/E not meaningful) and an ROE of -15.65%. Market capitalisation stands at $6.2B.
Balance sheet quality for BLTE: debt-to-equity ratio of 0.00, current ratio of 33.56 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 7.97 |
| EV / EBITDA | -53.7 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BLTE | Belite Bio, Inc | $6.2B | 7.97 | -15.6% | |
| KOD | Kodiak Sciences Inc. | $6.2B | 100.98 | -273.2% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $139.2B | 35.33 | 6.66 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $103.2B | 14.63 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.8B | 20.56 | 2.79 | 15.1% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $58.6B | 43.93 | 6.97 | 16.9% |
Price
| Price | $154.01 (closing price, November 4, 2026) |
| Market Cap | $6.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -15.65% |
| Return on Invested Capital | -15.28% |
| Return on Assets | -12.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: KOD · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks